Pulmonary complications of polymyositis and dermatomyositis

被引:71
作者
Fathi, Mairyarn
Lundberg, Ingrid E. [1 ]
Tornling, Goeran
机构
[1] Karolinska Inst, Karolinska Univ Hosp, Rheumatol Unit, Dept Med, SE-17176 Stockholm, Sweden
[2] Karolinska Inst, Dept Med, Karolinska Univ Hosp, Div Resp Med & Allergy, Stockholm, Sweden
关键词
polymyositis; dermatomyositis; interstitial lung disease;
D O I
10.1055/s-2007-985666
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Polymyositis and dermatomyositis are systemic inflammatory diseases with unknown etiology and prognosis. Pulmonary involvement is increasingly recognized to be a major complication and a common cause of morbidity and mortality in these diseases. Thus a thorough pulmonary evaluation is necessary to permit appropriate management. There are three categories of pulmonary complications in myositis: aspiration pneumonia, hypoventilation, and interstitial lung disease (ILD). ILD is a frequent pulmonary complication in patients with myositis, and respiratory symptoms are not reliable signs for diagnosis. The strongest predictive factor for ILD in patients with myositis is the presence of antihistidyl transfer ribonucleic acid (tRNA) synthetase antibodies (anti-Jo-1), but ILD may also be present in patients without these autoantibodies. Therefore, all patients with polymyositis or dermatomyositis should be investigated with chest radiography, high-resolution computed tomography, and lung function tests.
引用
收藏
页码:451 / 458
页数:8
相关论文
共 77 条
[61]   The long-term outcome of anti-Jo-1-positive inflammatory myopathies [J].
Späth, M ;
Schröder, M ;
Schlotter-Weigel, B ;
Walter, MC ;
Hautmann, H ;
Leinsinger, G ;
Pongratz, D ;
Müller-Felber, W .
JOURNAL OF NEUROLOGY, 2004, 251 (07) :859-864
[62]   Interstitial lung diseases associated with amyopathic dermatomyositis [J].
Suda, T. ;
Fujisawa, T. ;
Enomoto, N. ;
Nakamura, Y. ;
Inui, N. ;
Naito, T. ;
Hashimoto, D. ;
Sato, J. ;
Toyoshima, M. ;
Hashizume, H. ;
Chida, K. .
EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (05) :1005-1012
[63]   Polymyositis/dermatomyositis and interstitial lung disease: A new therapeutic approach with T-cell-specific immunosuppressants [J].
Takada, K ;
Nagasaka, K ;
Miyasaka, N .
AUTOIMMUNITY, 2005, 38 (05) :383-392
[64]  
TAKIZAWA H, 1987, J RHEUMATOL, V14, P102
[65]  
TANIMOTO K, 1995, J RHEUMATOL, V22, P668
[66]   Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis [J].
Tansey, D ;
Wells, AU ;
Colby, TV ;
Ip, S ;
Nikolakoupolou, A ;
du Bois, RM ;
Hansell, DM ;
Nicholson, AG .
HISTOPATHOLOGY, 2004, 44 (06) :585-596
[67]  
Targoff Ira N., 1997, Current Opinion in Rheumatology, V9, P527, DOI 10.1097/00002281-199711000-00008
[68]   Expression of tumor necrosis factor-alpha in muscles of polymyositis [J].
Tateyama, M ;
Nagano, I ;
Yoshioka, M ;
Chida, K ;
Nakamura, S ;
Itoyama, Y .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1997, 146 (01) :45-51
[69]   INTERSTITIAL LUNG-DISEASE IN POLYMYOSITIS AND DERMATOMYOSITIS - CLINICAL-FEATURES AND PROGNOSIS AS CORRELATED WITH HISTOLOGIC-FINDINGS [J].
TAZELAAR, HD ;
VIGGIANO, RW ;
PICKERSGILL, J ;
COLBY, TV .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1990, 141 (03) :727-733
[70]  
Tomsic M, 2000, WIEN KLIN WOCHENSCHR, V112, P728